Although the mortality rates of clear cell renal cell carcinoma (ccRCC) have decreased in recent years, the clinical outcome remains highly dependent on the individual patient. Therefore, identifying novel biomarkers for ccRCC patients is crucial.
Background
Clear cell renal cell carcinoma (ccRCC) is the most common malignancy in the kidneys, which has increasing incidence and mortality rates worldwide [1] . Treatments for localized ccRCC can vary from radio-frequency ablation to partial or radical nephrectomy; however, once RCC progresses to distant metastasis, the curative effect of current targeted drug therapies is limited [2] . Additionally, when first diagnosed, approximately 30% patients already have metastasis [1] . Therefore, it is urgent to understand the underlying mechanism of metastasis and to identify novel biomarkers with greater prognostic values.
The TNM staging system has been used for over 80 years and is important for estimating the outcome of various cancers; however, it provides an incomplete prognostic value [3] [4] [5] . Clinical outcomes can differ significantly among patients with the same tumor stage [6] . Despite surgical removal of the tumor, a subgroup of patients experience recurrence, indicating that at the time of curative surgery, the metastasis was already present [7] . However, no consensus was reached regarding the surveillance protocols of RCC, and no available tumor-associated biomarkers can predict recurrence in patients who may have benefited from earlier therapy [8] . Previous studies in colorectal cancer proposed several gene signatures and proved to be useful in predicting prognosis [9] [10] [11] . In this study, we divided patients from the Cancer Genome Atlas database into a non-metastasis group and a metastasis group in order to screen the differently expressed genes. Furthermore, we constructed a risk scoring system based on upregulated genes involved in metastasis to identify a multi-gene signature for use as an independent predictor for ccRCC.
Material and Methods

Data collection
The TCGA database contains large cohorts of genomic abnormalities and clinical information across the world, and is publicly available. RNA sequencing counts data from the ccRCC cohort, which consists of 539 tumor samples and 72 normal tissues, were obtained from the TCGA data portal (https://tcga-data.nci.nih.gov/tcga/). Clinical data pertaining to patients' age, gender, grade, stage, survival and recurred/progressed outcome were also acquired from the TCGA data portal. We divided patients based on N stage and M stage into 2 groups. Patients with both M0 and N0 stage were assigned to the nonmetastasis group, whereas M1 and/or N1 patients were assigned to the metastasis group.
Identification of differentially expressed genes (DEGs)
We identified the DEGs using the edgeR package, with a cutoff of adj.p-value <0.05 and a |logFC| >2 [12] . DEGs were visualized with volcano plot through the gplots package in R (version 3.5.2).
Enrichment analysis of DEGs
We performed a functional enrichment analysis of the DEGs using DAVID (Database for Annotation, Visualization, and Integrated Discovery) to determine the gene ontology (GO) categories by using cellular component (CC), molecular function (MF), or biological processes (BP), as well as KEGG (Kyoto Encyclopedia of Genes and Genomes) pathway [13] . P<0.05 was defined as significant enrichment. An online web tool was used to visualized these processes (http://www.ehbio.com/ImageGP/).
Construction of PPI network
We used the STRING database to retrieve the protein-protein interaction (PPI) network of DEGs, and we used Cytoscape software to reconstruct and visualize the network [14, 15] . Individual network modules with 10 or more nodes were shown.
Univariate and multivariate Cox analysis to screen the candidate genes CcRCC samples were separated into 2 groups according to the median gene expression. Then, age (£60/>60), sex (male/female), grade (G1-G2/G3-G4), stage (I-II/III-IV), T stage  (T1-T2/T3-T4) , N stage (N0/N1), M stage (M0/M1), specific gene, and survival data (time and state) were all included into the Cox regression model to preform univariate and multivariate Cox analysis using SPSS 22.0 (IBM Corporation, Armonk, NY, USA).
Establishment of a prognostic signature based on candidate genes
The stepwise multivariate Cox regression analysis model was constructed based on the candidate genes to extract the mRNAbased model with the best predictive ability. The criteria for inclusion and exclusion was set as P<0.05. Subsequently, the risk score for each patient was computed using the mRNA-based prognostic model as follows: Risk score=expRNA1*bRNA1+ expRNA2*bRNA2+expRNA3*bRNA3+…expRNAn*bRNAn, where expRNA was the mRNA expression level and bRNA referred to the regression coefficient derived from the multivariate Cox hazards regression analysis. Based on the risk score for each patient, patients from the TCGA database were separated into 2 groups: a low-risk group and a high-risk group. KaplanMeier survival analysis was performed to assess differences in 4402 overall survival and disease-free time of patients using a logrank test in GraphPad Prism 7.0. In addition, the receiver operating characteristic (ROC) curve was utilized to evaluate the specificity and sensitivity of the survival and disease-free prediction by the area under the curve using the R package "survivalROC" [16] . Heatmaps and clustering were generated based on the ClustVis open web tool [17] .
Predictive value assessment
To evaluate the clinical value of our risk scoring system, we analyzed the clinical characteristics and risk scores in univar- 
Results
Differentially expressed genes related to the metastasis of ccRCC
In this study, we defined M0 and N0 patients as the non-metastasis group (198 cases), while M1 and/or N1 patients (89 cases) were defined as the metastasis group. Altogether, 263 genes were found to be dysregulated according to the cutoff criteria, among which, 101 genes were upregulated and 162 gene were downregulated ( Figure 1, Supplementary Table 1 ). Functional enrichment analysis of gene ontology revealed that dysregulated genes were mainly enriched in sequence-specific DNA binding, receptor binding, the extracellular region, the integral component of the plasma membrane, ion transmembrane transport, and insulin receptor signaling pathway. KEGG pathway analysis indicated that genes were primarily enriched in neuroactive ligand-receptor interaction and synaptic vesicle cycle (Figure 2) . Moreover, the PPI network consisted of 10 modules, which included 255 nodes and 316 edges. The most significant module is shown in Figure 3 .
Survival-related genes by Cox regression analysis
To identify key genes that may affect overall survival of patients, we performed Cox proportional hazard regressions analysis on upregulated genes. Twenty key genes were demonstrated to influence overall survival: OTX1, FOXE1, FAM83A, HMGA2, KRT6A, DPYSL5, ANXA8, MATN4, ROS1, CSMD3, MAGEC3, AMER2, CPLX2, PI3, KRT13, ERVV-2, ANKFN1, VTN, NFE4, and ZNF114 ( Figure 4 ).
Construction of a risk scoring system based on candidate genes
For the purpose of extracting a signature that possesses the best predictive efficacy, 20 key genes were subjected to the stepwise multivariate Cox regression model. Results from the model revealed a total of 5 genes that proved to be significant survival predictors. The related information of these 5 genes is shown in Table 1 . Subsequently, the risk score for each patient was computed as follows: expOTX1*0.725+expM ATN4*0.473+expPI3*0.548+expERVV-2*0.458+expNFE4*0.410. According to the median risk score, we assigned these scores to the low-or high-risk group. Overall survival analysis showed that the low-risk group had better prognoses compared with the high-risk group ( Figure 5A ). The prognostic ability of the 5-gene signature was assessed by the AUC value of the ROC curve. The AUC was 0.687 for 3-year and 0.695 for 5-year overall survival, indicating a good performance of the 5-gene signature ( Figure 5C , 5E). Risk scores in the low-risk group ranged from 0 to 0.215232506445 and ranged from 0.215490360701 to 360.615372760823 in the high-risk group ( Figure 5G ). Disease-free survival analysis revealed a significant difference between the 2 groups, with the low-risk group having a longer disease-free time ( Figure 5B ). In the ROC curve, the AUC for 3-year disease-free survival was 0.674 and 0.681 for 5-year disease-free survival ( Figure 5D , 5F). Risk scores in the low-risk group ranged from 0 to 0.187870897657 and from 0.194574172497 to 360.615372760823 in the high-risk group ( Figure 5H ). Figure 6 shows the expression patterns of all the 5 genes in the 2 groups. The expression of OTX1, MATN4, and PI3 were significantly higher in the high-risk group in the 2 cohorts ( Figure 7 ). 
Assessment of gene signature prognostic value
Univariate Cox regression analysis of the prognostic power of our risk scoring system showed that age, grade, stage, T stage, N stage, M stage, and risk level were all indicators of poor outcome. Then, these 7 indexes were entered into the multivariate Cox regression model, showing that risk level could be treated as an independent prognostic factor ( Table 2 ). Furthermore, as is shown in Table 3 , based on the chi-square test, risk level was significantly correlated with sex, grade, tumor stage, T stage, N stage, M stage, and vital status. Collectively, our results demonstrate that our 5-gene signature is a robust tool for use in predicting prognosis and recurrence.
Discussion
CcRCC has been shown to display distinct variability in clinical outcome, possibly due to the intrinsic molecular heterogeneity, which remains unclear, especially with regard to the mechanism of distant metastasis [18] . Moreover, the clinically available parameters, such as TNM stage and Fuhrman grade, are indispensable for prognostic prediction [19] . Nevertheless, there remains an urgent need to detect prognostic biomarkers due to the high heterogeneity in ccRCC.
In the current study, we performed bioinformatic analysis between the non-metastasis and metastasis ccRCC group to identify genes involved in metastasis. As a result, we found that 263 genes were dysregulated; functional enrichment analysis of these genes revealed that dysregulated genes were primarily enriched in sequence-specific DNA binding, receptor binding, extracellular region, integral component of plasma membrane, ion transmembrane transport, insulin receptor signaling pathway, neuroactive ligand-receptor interaction, and synaptic vesicle cycle. Most importantly, we identified a 5-gene panel signature (OTX1, MATN4, PI3, ERVV-2, and NFE4) after the Cox proportional hazards regression analysis. Then, a risk score was acquired by combing the 5 genes. Recently, Wei et al. also identified key genes involved in the metastasis of ccRCC using similar bioinformatics methods [20] . However, in our study, 
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to promote colorectal cancer progression in vitro through epithelial-mesenchymal transition and hepatocellular carcinoma progression by regulation of the ERK/MAPK pathway [24, 25] . In bladder cancer, OTX1 combined with FGFR3 and TERT can function as a surveillance biomarker [26] . However, the role of OTX1 in ccRCC is still unknown. PI3, also called elafin, encodes an elastase-specific inhibitor that functions as an antimicrobial peptide [27, 28] . Caruso et al. demonstrated that elafin predicts poor outcome in ovarian and breast cancer patients, and it may play a role in tumor dormancy; moreover, it has been shown that elafin is an important therapeutic target for breast and ovarian carcinoma [29] [30] [31] . MATN4, a member of the von Willebrand factor A domain-containing protein family, has not been widely studied in cancer to date [32] . A study showed that under acute stress, CXCR4 and MATN4 are involved in the regulation of hematopoietic stem cells proliferation and expansion [33] . ERVV-2 is functionally important in reproduction, and NFE4 is involved in preferential expression of the gamma-globin genes in fetal erythroid cells [34, 35] . These 2 genes have not been well defined in cancer biology, particularly in ccRCC.
In summary, our study used an integrated analysis to identify differentially expressed genes that participate in metastasis of ccRCC. Furthermore, we constructed a 5-gene signature with a quantitative index that exhibited an independent prognostic value. In the future, this 5-gene signature may be used to identify patients who need regional lymph node dissection during radical nephrectomy [36] . Since these 5 genes are correlated with poor outcome, they might be therapeutic targets for ccRCC. However, in vivo and in vitro studies are still needed to reveal the biological functions of these predictive mRNAs in ccRCC.
Conclusions
We identified differentially expressed genes that may participate in the metastasis of ccRCC. More importantly, we established a predictive signature based on the expression of OTX1, MATN4, PI3, ERVV-2, and NFE4, which could serve as significant progressive and prognostic biomarkers for ccRCC. 
